Moderna Settlement Caps Covid-19 Vaccine Patent Liability at $2.25 Billion, Sets Stage for Federal Circuit Appeal on Government-Contractor Immunity

Moderna Inc. has finalized a settlement to resolve a high-profile patent infringement lawsuit concerning the lipid-nanoparticle (LNP) technology integral to its Spikevax Covid-19 vaccine and related mRNA products. The agreement caps Moderna’s potential exposure at $2.25 billion and strategically preserves a pivotal legal issue for appellate review, underscoring the case’s broader implications for government-contractor immunity in pandemic-era pharmaceutical development.

Under the terms announced, Moderna will pay $950 million in the third quarter to Arbutus Biopharma Corp. and Genevant Sciences GmbH, the patent holders alleging infringement of their LNP technology. Additionally, Moderna will pursue an appeal before the US Court of Appeals for the Federal Circuit challenging a district court ruling that largely rejected its government-contractor defense under Section 1498, a World War I-era statute that can shield contractors from patent liability when working on government projects.

Should the Federal Circuit uphold the lower court’s decision, Moderna has agreed to make an additional contingent payment of up to $1.3 billion, effectively pricing the risk associated with the appeal. Legal experts note this structure is unusual in patent litigation, where settlements rarely hinge on such substantial contingent payments tied to appellate outcomes. This arrangement ensures the Federal Circuit will have a live controversy to adjudicate, rather than a moot legal question.

"The contingent payment effectively prices the risk of Moderna’s government-contractor defense while preserving a live dispute for Federal Circuit review," said Coby Nixon, chair of Buchalter’s litigation practice group. He emphasized the broader significance of the appeal, which could influence how Section 1498 is applied to companies engaged in federally funded or emergency response programs.

Duke University law professor Arti Rai highlighted the potential ripple effects, noting that the Federal Circuit’s interpretation could deter or encourage companies from entering government procurement contracts if patent infringement liability protections are clarified or limited.

The settlement follows a series of rulings by US District Judge Joshua D. Wolson, who issued a consent judgment confirming that Moderna infringed the asserted patents and that the patents are valid. The judge previously ruled that Section 1498 shields Moderna from liability for approximately 6.2 million vaccine doses administered directly to US government employees but does not extend immunity to vaccines distributed through commercial channels.

Arbutus and its licensing partner Genevant initiated the lawsuit in 2022, asserting that Moderna’s Covid-19 vaccine infringes their patented LNP technology, which employs lipid nanoparticles to deliver genetic material into cells. The dispute was widely regarded as a critical test of intellectual property rights arising from the rapid development and deployment of Covid-19 vaccines.

In parallel litigation, Arbutus and Genevant have filed similar claims against Pfizer Inc. and BioNTech SE regarding their Covid-19 vaccine in federal court in New Jersey. However, experts suggest Moderna’s appeal may have limited impact on that case, as Pfizer’s involvement in Operation Warp Speed differed significantly from Moderna’s.

The settlement was reached less than a week before a jury trial was scheduled to begin in the District of Delaware. Recent rulings had narrowed the scope of the trial by limiting Moderna’s ability to invoke Section 1498 broadly and restricting certain patent-invalidity defenses, while requiring Arbutus to prove literal infringement of specific formulation claims.

"The recent rulings gave both sides reason to question their chances at trial, which likely influenced the settlement calculus," said Daniel L. Shores, a biotech patent specialist at Rothwell, Figg, Ernst & Manbeck PC. He noted that the remaining issues involved complex technical questions about vaccine formulation, posing significant risks for both parties if left to a jury.

University of Illinois law professor Jacob Sherkow, who studies biotechnology patents, had predicted the case could yield the largest patent verdict in US history. He observed that the settlement amount aligns with anticipated damages exposure and described the decision to preserve the Section 1498 issue for appeal as "very interesting," given the statute’s ambiguous application in the pandemic context.

Kevin E. Noonan, a partner at McDonnell Boehnen Hulbert & Berghoff LLP, remarked that settlements preserving a single legal issue for appeal are not uncommon, but the scale and structure of this agreement are distinctive. He added that resolving the infringement dispute while maintaining the appeal may help Moderna secure clearer rights to use the LNP technology in its expanding pipeline of mRNA-based therapies, including potential cancer vaccines.

The Moderna settlement thus not only concludes a major patent dispute but also sets the stage for a consequential Federal Circuit ruling on government-contractor immunity under Section 1498. The outcome could shape the legal landscape for patent rights and liability protections in federally supported biomedical innovation for years to come.